Description
This is our first report on Mirati Therapeutics Inc., a pharmaceutical firm specializing in cancer treatment. The company is entering a critical period as it works towards fulfilling its mission of providing groundbreaking therapies for patients. The company has shown significant potential with a robust pipeline and innovative programs targeting areas of cancer with large unmet needs. The recent launch of KRAZATI, which received the FDA’s approval, was a significant achievement, and the drug’s differentiated profile has led to a strong initial response from the market, indicating potential for continued growth.
Our Report Structure:
⦁ Company Overview
⦁ Investment Thesis
⦁ Key Drivers
⦁ Historical Quarterly Statement Analysis – Income Statement & Cash Flows
⦁ Historical Quarterly Balance Sheet Analysis
⦁ Historical Annual Financial Statement Analysis
⦁ Analysis Of Key Financial Ratios
⦁ Financial Forecasts For 3 Years
⦁ Forecasting The Capital Structure & Net Debt
⦁ Discounted Cash Flow Valuation
⦁ Trading Multiples
⦁ Key Risks
⦁ Disclosures
Want unlimited access to our reports? Purchase our $99 annual subscription!
